Brief: Xortx Initiates Dosing Of Human Subjects In The Xrx-Oxy-101 Clinical Trial
03/05/2022 12:39
May 3 (Reuters) - XORTX Therapeutics Inc XRTX.V :
* XORTX INITIATES DOSING OF HUMAN SUBJECTS IN THE
XRX-OXY-101
CLINICAL TRIAL
Source text for Eikon: ID:nGNX4v38jN
Further company coverage: XRTX.V
((reuters.briefs@thomsonreuters.com;))
Recent news on XORTX Therapeutics
See all newsBrief: Xortx Outlines Anticipated Health Canada Clinical Trial Application For Xrx-026 For Gout
Brief: XORTX Therapeutics Announces Initiation Of Drug And Tablet Manufacturing For XRx-026 Program
Brief: Xortx Announces Termination And Postponement Of Investor Relations Program
Brief: XORTX Announces Director Resignation
Brief: Xortx Announces Us$5 Million Public Offering